This patient on natalizumab has no evident disease activity, but progressive and accelerated brain volume loss. She is keen to switch to HSCT or alemtuzumab. What should she do?
0 subscriptions will be displayed on your profile (edit)
Skip for now
For your security, we need to re-authenticate you.
Click the link we sent to , or click here to sign in.